Member Info for Saxondale

This is mega - only another 40p and I'll be back in the blue ;-)
No funds to top up this week , but at least I didn't sell .

First class tickets to Boston !
I picked up another few at £4.73 in Duty Free this morning . Haven't got on the plane yet and they're already showing significant shareholder value ( ok , only by 1.5p but it's a start)

£5 odd is such a healthy platform to be negotiating partner deals from .

Looking forward to tomorrow , I wonder if we get another cheeky RNS . Surely they must have updates and to use the Results day presentation would make a powerful impact .

Me too Hawkes . NCYT RNS'd the massive DHSC order , but it took a while for the market to react . SNG was instantaneous . SP is up and down like NCYT in the early days , traders delight , but the market just doesn't know where to peg it . But like you I reckon it has plenty of legs as the real stuff hasn't yet begun .

Maybe more joining too -
The Company will consider adding to the Board and to the Technical Advisory Committee to further expand the Company's skill sets.

Three big hitters joining the team , and look at their skill sets .
Callum still connected - but a lot of work ahead - so more hands needed.
This is building up nicely , well done Shaun , and thanks Callum too .

Well that post didn't age well . I take it all back - we're on track !

Those hospital figures are for Massachusetts by the way . I'm guessing that's where Hibiscus will be trialed , as no study locations shown on Clinical Gov site yet .

If the delay in Hibiscus starting was lack of patients , that situation has changed drastically in the last month .
Hibiscus shows as being registered on NIH side on 27th April
On that date there were approx 550 ( 61 in ICU ) in hospital , but that figure sank in a straight line to about 100 ( approx 12 in ICU ) until Aug

This month ( Aug ) - hospitalisations have risen from 135 ( 17 in ICU ) to 575 ( 140 in ICU )
Thats a fourfold increase , and nearly 10 fold increase into ICU - In a month !

In my opinion it has been borderline criminal that trials on Traumakine have been sidelined , ignored , or pushed from pillar to post , when the science shows it has a REAL chance to improve patients condition with Covid , and ARDS .
Nearly 2 years into the pandemic , and a drug that is known to target the biggest symptom of Covid , no evidence has been published to show that it has yet to be given to a single Covid patient on any trial in the world ?? You couldn't make it up .

WHO - sent 1000's of doses - never used them , or if they did , threw results in the bin
REMAP CAP - created a situation where it would very unlikely get a look in ( steroid as standard of care )
HIBISCUS - funded by DofD - but then seemingly mothballed for whatever reason .

It doesn't smell right .
Maybe it is just the way of the world that small pharma have to stand at the back of the queue , but it still doesn't make it right .

166.5 on the bid .
I guess that
1.) This info only appeared less than an hour ago - takes a while for people to find out
2.) Its still unconfirmed other than everyone taking 2+2 and making 4
3.) No official announcement .

If its true then anything under a couple of quid would be a bargain considering what comes next .

Still in auction - can't buy a bean

Yeah i wouldn't expect an immediate RNS , but it is pretty big news and will affect share price , so if its true , expect at least a confirmation at some point , just to clarify .
It's pretty mega news if true .

Yep that looks like a solid bit of evidence on the Clinical Gov site .
Well spotted .
Dr Castro said they would apply for EUA at the same time as moving to P3 if I remember right .

This surely will be RNS material .

Anyone heard of a share doing 100% twice in 2 days ?
If it keeps on like this , I'm starting to think this share may break a record

That phrase ' let your winners run ' comes to mind today .
Shes flying

Yes the whole GLP etc seems a bit fishy .
ABDX caught up in the middle .
But now the reality is , the Govt are going to be using a lot of these tests , and so the shenanigans have to stop .
Lots of interest . Should be interesting !

Lime , I'm pretty sure Markku has been in discussions with potential suitors with Bex since the P1 days . Each potential partner may want to see success in their desired area before committing to the asking price . But as the trials expanded due to the initial great data , so it became a balance between taking what was on the table , or pushing further with the research in order to prove up more cohorts , and with it raise the price and the options available. Each placing has diluted the value of our shares at the time , but with the effect of raising the sale price at the end . The grants and loans have been a real blessing for us shareholders , but also show what confidence there is in this becoming a success .
I really have no clue as to how this story will go from here , how many interested parties there are , or if one big Pharma will want to take the whole project for themselves . Or if Faron really do see themselves seeing Bex through the pivotal trials themselves by selling or licensing Traumakine somehow . I just don't see that personally however , not until Hibiscus or some other P3 takes place .
At the moment it looks like we have at least 4 solid tumour cohorts that could move to P3 .
We've got new data coming on Ovarian and Lung cancer cohorts .
Theres the soluble clever 1 research that has been ongoing for months and overdue an update .
And then there's a growing list of complimentary targets where Bex could be used with other existing therapies .
Add to that , an SP that's been creeping up and up for the last few months , and members of the Faron/Hollmen team getting front page spreads and more media exposure than ever before .
We've got a Proactive Investor forum evening booked for later in Sept , and Hollmen labs talking about new findings in a cancer summit also .
All we need now , is for someone to just tell us whats actually happening lol .

Well I bought some at 51p , then went for a cycle , thinking , why did you buy a share thats just gone up 70% in a day , classic schoolboy error . Fully expecting to see a 45-47p .
Looks like even muppets like me can get it right now and again lol .

Another example of a biotech in mid trials being bought up by a big pharma .

This time Pfizer paying $2.3 billion for a blood cancer biotech Trillium Theraputics .

Andy Schmeltz, global president of Pfizer’ oncology division, said the acquisition “reinforces our commitment to pursue scientific breakthroughs”.

Anyone got his email ?

https://www.ft.com/content/d673c756-eb4c-45e1-822d-b520158768c6

Yes Laplom , looks like Lago are selling the most onto the market , and the likes of Dankse Bank & OP Corperate bank are hoovering them up .

I'm sure the Finnish scientific community , particularly around Turku University is a close knit group . I got quite a few likes on a twitter comment regarding Hollmen Lab from people who follow her . I think excitement is building over there . A success for Faron & Hollmen Lab will bring more investment and grants into that area for sure , and will shine a light on the work they are doing .
With The Finnish Academy cutting funding by $40million , something like Bexmarilimab , and all its potential spin offs and research projects would be a real boost .